Feedback / Questions
EVO301 - Evommune
https://www.businesswire.com/news/home/20260210709064/en/Evommune-Announces-Positive-Top-line-Data-from-Phase-2a-Proof-of-Concept-Trial-of-EVO301-in-Moderate-to-Severe-Atopic-Dermatitis
Feb 10, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next